According to research conducted by KPMG, “2015 was a record breaker for M&A in pharma, medical and biotech with deals worth $575 billion.” 2016 promises to be another year of high M&A activity as “dealmakers expect to increase their number of acquisitions…” This same research cited that life sciences is one of the top two industries that will experience the greatest number of M&A deals. Most of the life sciences organizations are undergoing significant structural changes to better align their sales force with the needs of the healthcare market and to curtail the loss of revenue and market share, due to patent expirations and increasing competition from generics.
To help life sciences sales organizations navigate the common challenges associated with M&A, SPI Health™ developed a learning and enablement solution based on a continual learning model, focusing primarily on quickly and effectively unifying and preparing sales teams to be a value-add resource for their customers. Life sciences organizations that implement the M&A Survival Kit solution should expect their sales force to achieve the following goals in as little as 6 months:
High-Level View of the M&A Survival Kit
To learn more about the SPI Health solutions visit our Comprehensive Methodologies Page